Cannabis use in Crohn’s disease: a systematic review and meta-analysis of randomized controlled trials (RCTs)
- 17 January 2025
- journal article
- research article
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 194 (2) , 439-446
Abstract
Objective This meta-analysis aims to systematically evaluate the efficacy and safety of cannabis in the management of Crohn’s disease (CD) by synthesizing evidence from randomized controlled trials (RCTs). By adhering to the 2020 PRISMA guidelines and registering the study protocol with PROSPERO, this research intends to offer robust, evidence-based recommendations for healthcare practitioners on the therapeutic potential and clinical implications of cannabis use in CD management. Methods A literature search encompassing PubMed, Google Scholar, and the Cochrane Library was conducted to identify relevant RCTs comparing cannabis to placebo or standard therapy in CD patients. Inclusion criteria focused on outcomes such as remission rates, C-reactive protein (CRP) levels, quality of life (QoL), and adverse events (AEs). Statistical analysis using RevMan 5.3 involved weighted mean differences (MD) and 95% confidence intervals to compare outcomes between the cannabis and control groups. Results The meta-analysis revealed significant findings regarding the impact of cannabis on CD management. The cannabis group exhibited significantly higher clinical remission rates at 8 weeks compared to the control group, with low heterogeneity [MD = − 67.98; 95% CI: (− 100.68, − 35.29)]. However, a statistically significant improvement in QoL was observed in the placebo group compared to the cannabis-treated group [MD = 19.62; 95% CI (14.24 to 25.00)]. There was a non-significant lowering in serum CRP levels compared to the placebo group [MD: − 0.51; 95% CI: (− 1.05, 0.02)]. Conclusion The study concludes that cannabis shows promise as a therapeutic option for CD, demonstrating higher remission rates and potential benefits for disease management. However, it also highlights the need for larger, standardized research studies to solidify conclusions regarding efficacy, safety, and biomarker responses in CD patients.Keywords
This publication has 28 references indexed in Scilit:
- Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled TrialJournal of Crohn's and Colitis, 2021
- International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain managementPain, 2021
- Association Between Level of Fecal Calprotectin and Progression of Crohn's DiseaseClinical Gastroenterology and Hepatology, 2019
- Positive and Negative Effects of Cannabis and Cannabinoids on HealthClinical Pharmacology & Therapeutics, 2019
- Crohn Disease: Epidemiology, Diagnosis, and ManagementMayo Clinic Proceedings, 2017
- Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled TrialDigestive Diseases and Sciences, 2017
- Cannabis use and mental health-related quality of life among individuals with depressive disordersPsychiatry Research, 2015
- Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled StudyClinical Gastroenterology and Hepatology, 2013
- The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunityTrends in Molecular Medicine, 2012
- Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitisInflammatory Bowel Diseases, 2009